Cargando…

Noninvasive Testing Using Magnetic Resonance Imaging Techniques as Outcomes in Nonalcoholic Steatohepatitis Clinical Trials: How Full Is the Glass?

Detalles Bibliográficos
Autores principales:	Noureddin, Nabil, Schattenberg, Jörn M., Alkhouri, Naim, Noureddin, Mazen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996378/ https://www.ncbi.nlm.nih.gov/pubmed/32025600 http://dx.doi.org/10.1002/hep4.1473

Ejemplares similares

Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
por: Noureddin, Mazen, et al.
Publicado: (2019)

Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis
por: Jacobson, Ira M., et al.
Publicado: (2022)

Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH Treatment
por: Alkhouri, Naim, et al.
Publicado: (2019)

Simple diagnostic algorithm identifying at-risk nonalcoholic fatty liver disease patients needing specialty referral within the United States
por: Alkhouri, Naim, et al.
Publicado: (2022)

Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART Trial)
por: Loomba, Rohit, et al.
Publicado: (2015)

The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database
por: Alkhouri, Naim, et al.
Publicado: (2022)

Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
por: Eskridge, Wayne, et al.
Publicado: (2023)

Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort
por: Khoudari, George, et al.
Publicado: (2019)

Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
por: Younossi, Zobair M., et al.
Publicado: (2021)

Designing Clinical Trials in Pediatric Nonalcoholic Steatohepatitis: Tips for Patient Selection and Appropriate Endpoints
por: Alkhouri, Naim, et al.
Publicado: (2019)

Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis
por: Noureddin, Mazen, et al.
Publicado: (2023)

Metabolomic‐based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts
por: Mayo, Rebeca, et al.
Publicado: (2018)

Review article: role of glucagon‐like peptide‐1 receptor agonists in non‐alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know
por: Barritt, A. Sidney, et al.
Publicado: (2022)

What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?
por: Alkhouri, Naim, et al.
Publicado: (2021)

Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge
por: Steggerda, Justin A, et al.
Publicado: (2020)

Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017–2018 transient elastography data and application of machine learning
por: Noureddin, Mazen, et al.
Publicado: (2022)

Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV
por: Michel, Maurice, et al.
Publicado: (2022)

Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
por: Anstee, Quentin M., et al.
Publicado: (2023)

Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scores
por: Noureddin, Mazen, et al.
Publicado: (2023)

Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease
por: Kim, Young Seok, et al.
Publicado: (2013)

Noninvasive markers: a double-edged sword that stratifies nonalcoholic steatohepatitis
por: Chung, Goh Eun, et al.
Publicado: (2013)

Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Noninvasive measure of treatment response in non‐alcoholic steatohepatitis: Insights from EMMINENCE and meta‐analysis
por: Davison, Beth A, et al.
Publicado: (2021)

Diet Quality Association with Nonalcoholic Fatty Liver Disease by Cirrhosis Status: The Multiethnic Cohort
por: Park, Song-Yi, et al.
Publicado: (2020)

Diabetes and Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease
por: Teng, Pai-Chi, et al.
Publicado: (2023)

Development of a novel machine learning model to predict presence of nonalcoholic steatohepatitis
por: Docherty, Matt, et al.
Publicado: (2021)

Formulation for Effective Screening and Management of Nonalcoholic Steatohepatitis: Noninvasive NAFLD Management Strategy
por: Hirose, Kanae, et al.
Publicado: (2016)

Clinical and sociodemographic determinants of disease progression in patients with nonalcoholic steatohepatitis in the United States
por: Ruiz-Casas, Leonardo, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017–2018
por: Truong, Emily, et al.
Publicado: (2022)

A circulating microRNA signature as noninvasive diagnostic and prognostic biomarkers for nonalcoholic steatohepatitis
por: Liu, Jie, et al.
Publicado: (2018)

The Role of Noninvasive (13)C-Octanoate Breath Test in Assessing the Diagnosis of Nonalcoholic Steatohepatitis
por: Fierbinteanu-Braticevici, Carmen, et al.
Publicado: (2022)

Hepatitis Delta: Epidemiology, Diagnosis and Management 36 Years After Discovery
por: Noureddin, Mazen, et al.
Publicado: (2013)

Current and Potential Therapies Targeting Inflammation in NASH
por: Albhaisi, Somaya, et al.
Publicado: (2021)

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
por: Alnimer, Lynna, et al.
Publicado: (2023)

Necroptosis in Nonalcoholic Steatohepatitis
por: Gautheron, Jérémie, et al.
Publicado: (2015)

Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH
por: Del Ben, Maria, et al.
Publicado: (2018)

Incidence of Complications from Percutaneous Biopsy in Chronic Liver Disease: A Systematic Review and Meta-Analysis
por: Thomaides-Brears, Helena B., et al.
Publicado: (2021)

Effect of Colesevelam on Liver Fat Quantified by Magnetic Resonance in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial
por: Le, Thuy-Anh, et al.
Publicado: (2012)

Alcoholic vs. Nonalcoholic Steatohepatitis: Vascular Branching Heterogeneity on Magnetic Resonance Imaging as a Diagnostic Marker
por: Garrido, Daniel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hq2mrlrv332k1ae1lrmjakg3uk